middle.news
Dimerix Secures Extended US Patent for DMX-652 Targeting Acute Kidney Injury
8:46am on Thursday 23rd of July, 2026 AEST
•
Biotechnology
Read Story
Dimerix Secures Extended US Patent for DMX-652 Targeting Acute Kidney Injury
8:46am on Thursday 23rd of July, 2026 AEST
Key Points
US patent granted for DMX-652 extending protection to 2043
Phase 2 clinical trial preparations underway for acute kidney injury
DMX-652 targets mitochondrial enzyme USP30 to prevent kidney damage
No approved therapies currently exist for acute kidney injury
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE